PARP-1作为内分泌抵抗性乳腺癌的新目标
Azzurra Zicarelli1,2, Marianna Talia3, Muriel Lainé4
1Ben May Department for Cancer Research, University of Chicago, Chicago, IL, USA. azzurra.zicarelli@unikore.it.
Journal of experimental & clinical cancer research : CR
|June 15, 2025
概括
聚 (ADP-ribose) 聚合酶-1 (PARP-1) 抑制有效地减少了雌激素受体阳性 (ERα) 乳腺癌 (BC) 的瘤生长,包括ESR1突变的病例. 这表明PARP-1是内分泌治疗耐药BC的有前途的治疗标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 在ERα阳性乳腺癌 (BC) 中,内分泌疗法 (ET) 耐药性是一个重大挑战.
- 获得的ESR1突变,如Y537S,导致构成性活跃的ERα,降低药物的疗效.
- 新的治疗标对于治疗具有激活ERα突变的BC患者至关重要.
研究的目的:
- 调查聚 (ADP-ribose) 聚合酶-1 (PARP-1) 作为ERα阳性BC的潜在治疗标.
- 确定PARP-1在BC进展中的作用,特别是在ERα突变的背景下.
- 在ET耐药BC的临床前模型中评估PARP-1抑制的疗效.
主要方法:
- 使用了ERα野生型和Y537S突变的BC细胞系 (MCF7,T47D) 和异种移植模型.
- 采用的技术包括免疫阻塞,ChIP测序和RNA测序.
- 评估细胞活力,增殖和瘤生长抑制,使用PARP-1抑制剂尼拉巴里布和ERα抗剂拉索福西芬.
主要成果:
- PARP-1的表达受ERα及其联合激活剂FoxA1.1的调节.
- 在野生类型和Y537S突变BC细胞中,PARP-1抑制抑制了ERα介导的增殖.
- 在异种移植模型中,尼拉巴里布治疗显著降低了瘤生长,降低了ERα信号的调节.
结论:
- 在ERα驱动的BC进展中,PARP-1起着至关重要的作用.
- 抑制PARP-1证明了对抗ET耐药ERα阳性BC的有效性.
- 在BC,PARP-1代表了全面治疗策略的有前途的治疗目标.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Mitogens and the Cell Cycle
7.0K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K


